On January 8, Health Manufacturing (a subsidiary of Ningbo HEALTH Gene Technologies Co.,Ltd.) and Beckman Coulter have signed a strategic cooperation agreement in Ningbo, marking their joint commitment to promoting localized innovation and technological research and development, and bringing more efficient and accurate IVD solutions to the China market. Through this partnership, Health Manufacturing will leverage Beckman Coulter's technological expertise and strategic investment to accelerate the research, development, and production of diagnostic products tailored to the needs of the China market, thereby driving the high-quality development of China In Vitro Diagnostics industry.
Distinguished Guests of the Ceremony:
· Ding Yu
Chairman and CEO of HEALTH Gene Technologies
· Jianwei Yu
Chairman of HEALTH BioMed Group
· Jianmin Liu
General Manager of Health Manufacturing
· Wentao Hu
General Manager of Clinical Diagnostic Section of HEALTH Gene Technologies
· Rosa Chen
President of Danaher China Clinical Diagnostics
Global Vice President of Beckman Coulter Coulter Clinical Diagnostics
General Manager of Beckman Coulter Coulter China
· Gary Guo
General Manager of Commercial Management of Beckman Coulter Coulter Clinical Diagnostics China
Strategic Vice President of Danaher China
General Maneger of Cepheid China
· Fiona Sun
Senior Director of Strategy and Business Development, Beckman Coulter Coulter Clinical Diagnostics
· Jane Wu
Operations Director, Danaher China Medical Diagnostics Platform
Senior Operations Director, Beckman Coulter Coulter Laboratory Systems (Suzhou) Co., Ltd.
“Beckman Coulter has consistently focused on China, committed to advancing the implementation of localized initiatives. The strategic partnership between Beckman Coulter and Health Manufacturing stands as a significant model of localized collaboration in recent years, reflecting the trust and collaborative spirit cultivated over three decades of shared endeavors between the two teams. Through this milestone strategic partnership, we hope that both parties will continue to enhance clinical laboratory testing capabilities through advanced in vitro diagnostic technologies, safeguarding the lives of more Chinese patients and contributing to the development of China's healthcare industry.”
Since establishing this strategic partnership in 2024, the two sides have further solidified the foundation for long-term and stable cooperation. Yu Ding, Chairman and CEO of HEALTH Gene Technologies, expressed his gratitude to Beckman Coulter for its trust in Health Manufacturing, and also looked forward to Beckman Coulter's synergy and empowerment of Health Manufacturing.
“We are honored to have entered into a strategic partnership with Beckman Coulter. This partnership not only demonstrates Beckman Coulter's trust and support for Health Manufacturing, but also provides us with powerful technical empowerment and opportunities for collaborative innovation. We look forward to working together to bring more innovative products and services to the Chinese medical market, improving the efficiency and accuracy of laboratory and clinical diagnosis, and benefiting more patients.”
Beckman Coulter has always adhered to its “Innovate for China” strategy, continuously strengthening its local manufacturing capabilities, continuously improving and accelerating the pace of local innovation and research and development, and actively expanding open local cooperation models. It has launched cooperation in multiple areas, including product innovation, distribution innovation, and business model innovation, working with more ecosystem partners, including Health Manufacturing, to create an ecosystem that promotes IVD product innovation and explores solutions that meet the needs of medical institutions at all levels.
The conclusion of this strategic partnership marks the beginning of in-depth cooperation between Health Manufacturing and Beckman Coulter in multiple areas, including product innovation, technological research and development, and market expansion. The two parties will jointly explore solutions that meet the needs of medical institutions at all levels in China, driving innovation and upgrading in China's in vitro diagnostics industry. In the future, Health Manufacturing will continue to uphold its innovation-driven philosophy and collaborate with global leaders such as Beckman Coulter to contribute to the high-quality development of China's healthcare industry!
About Beckman Coulter
Beckman Coulter is one of the global leaders in the field of in vitro diagnostics. As a key operating company within Danaher Corporation's Medical Diagnostics platform, we are committed to the mission of“Pursuing Medical Innovation, Dedicated to Diagnostics,”providing innovative and intelligent diagnostic solutions to healthcare institutions and laboratories worldwide. Under Danaher's“Innovate for China”strategy, Beckman Coulter is deeply committed to local production, local R&D innovation, and local collaboration, enabling more patients to benefit from high-quality diagnostic services and supporting the“Healthy China 2030”initiative.
About HEALTH Gene Technologies
Ningbo HEALTH Gene Technologies Co.,Ltd. (HGT) is a high-tech enterprise specialized in medical laboratory technology and related products R&D, manufacturing, marketing and services. The main business covers two fields of clinical diagnosis and forensic science. Holding to the corporate mission of “Safer Society, Healthier Life”, HGT, committed to providing comprehensive medical testing application solutions to molecular diagnosis, immunodiagosis, biochemical diagnosis for medical institutions and disease control centers at all levels, and provide complete technical solutions to DNA individual and kinship identification for public security systems and judicial institutions.
